2 results
Approved WMOCompleted
1. Overall survival (primary efficacy endpoint)2a. Efficacy: progression-free survival (PFS), overall response rate (ORR = CR + PR), and a clincal benefit rate (CBR) will be evaluated as CR + PR + SD for at least 3 months.2b. Safety: adverse events…
Approved WMOCompleted
To assess the feasibility of nano-MRI in the evaluation of locoregional lymph nodes metastases in patients with esophageal cancer whom underwent nCRT and to study the effect of nCRT on the detection of locoregional lymph nodes metastases with nano-…